Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: Eexperiences from the FertiProtekt network

Lupus

Volumn 21, Issue 9, 2012, Pages 953-958

  Henes, M ^a,d   Henes, J C ^b,d   Neunhoeffer, E ^a,d   Von Wolff, M ^c,d   Schmalzing, M ^b,d   Kotter I ^b,d   Lawrenz, B ^a,d  

^a University of Tuebingen Hospitals   (Germany)

^b University Hospital of Tuebingen   (Germany)

^c University Hospital for Women   (Switzerland)

^d Centres of the PROTEKT Network   (Germany)

Author keywords

Autoimmune disease; cyclophosphamide; fertility preservation; FertiPROTEKT; systemic lupus erythematosus

Indexed keywords

CYCLOPHOSPHAMIDE; GONADORELIN;

ADULT; COUNSELING; CRYOPRESERVATION; CYTOTOXICITY; DISEASE REGISTRY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY; PRIORITY JOURNAL; REPRODUCTIVE PROCEDURE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ZYGOTE;

ADULT; COUNSELING; CRYOPRESERVATION; CYCLOPHOSPHAMIDE; FEMALE; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RETROSPECTIVE STUDIES;

EID: 84863928729     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312442753     Document Type: Review

References (28)

1. Zink A, Minden K, List SM. Gesundheitsberichterstattung des Bundes: Entzündlich-rheumatische Erkrankungen. 2010; 49: 11-12. http://edoc.rki.de/documents/rki-fv/red8yNOhcqG2/PDF/221RfeT2UwYJ.pdf.
2. Fischer-Betz R, Wessel E, Richter J, Winkler-Rohlfing B, Willers R, Schneider M. Lupus in Germany: analysis with the German lupus self-help organization (LULA). Z Rheumatol. 2005 ; 64: 111-122 (Pubitemid 41213055)
3. Manger K, Wildt L, Kalden JR, Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev. 2006 ; 5: 269-272 (Pubitemid 44269020)
4. Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993 ; 119: 366-369 (Pubitemid 23310085)
5. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis. 1996 ; 55: 224-229 (Pubitemid 26122247)
6. Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol. 2002 ; 29: 2129-2135
7. Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus. 2004 ; 13 (8). 569-574 (Pubitemid 39145485)
8. Lawrenz B, Henes JC, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: Evaluation by using anti-Muellerian hormone. Lupus. 2011 ; 20 (11). 1193-1197
9. Gol M, Saygili U, Koyuncuoglu M, Uslu T. Influence of high-dose methotrexate therapy on the primordial follicles of the mouse ovary. J Obstet Gyneacol Res. 2009 ; 35: 429-433
10. Husein M, Pingle S. Effect of cyclosporine A at therapeutic and toxic doses on the superluteinized ovaries in BALB/c mice. Transplant Proc. 1992 ; 24: 1663-1668
11. Mattison DR, Chang L, Thorgeirsson SS, Shiromuzu K. Effects of cyclophosphamide, azathioprine, and mercaptopurine on oocyte and follicle number in C57BL/6N mice. Res Commun Chem Pathol Pharmacol. 1981 ; 31: 155-216
12. von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. Fertility preservation in women: a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet. 2011 ; 284 (2). 427-435
13. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005 ; 52: 2761-2767 (Pubitemid 41369104)
14. Cigni A, Faedda R, Atzeni MM, et al. Hormonal strategies for fertility preservation in patients receiving cyclophosphamide to treat glomerulonephritis: a nonrandomized trial and review of the literature. Am J Kidney Dis. 2008 ; 52: 887-896
15. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000 ; 9: 401-405 (Pubitemid 30487421)
16. Petri M, Brodsky R, Jones R. High dose cyclophosphamide can cause ovarian failure. Arthritis Rheum. 2004 ; 50 (Suppl 9). 408-408
17. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010 ; 122: 803-811
18. Clowse M, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: A meta-analysis. Journal of Women's Health. 2009 ; 18 (3). 311-319
19. Adashi EY. Long-term gonadotropin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms. Hum Reprod. 1994 ; 9: 1380-1397 (Pubitemid 24224015)
20. Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril. 2009 ; 92: 1803-1810
21. Casoli P, Tumiati B, La Sala G. Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol. 1997 ; 24: 1639-1640 (Pubitemid 27320711)
22. Elizur SE, Chian RC, Pineau CA, et al. Fertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents. Rheumatology. 2008 ; 47: 1506-1509
23. Ott J, Nouri K, Stögbauer L, Fischer EM, Lipovac M, Promberger R, et al. Ovarian tissue cryopreservation for non-malignant indications. Arch Gynecol Obstet. 2010 ; 281 (4). 735-739
24. Donnez J, Dolmans MM, Demylle D, et al. Live birth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004 ; 364 (9443). 1405-1410 (Pubitemid 39370715)
25. Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y. Fertility preservation: successful transplantation of cryopreserved ovarian tissue in a young patient previously treated for Hodgkin's disease. Oncologist. 2007 ; 12 (12). 1437-1442
26. Andersen CY, Rosendahl M, Byskov AG, et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod. 2008 ; 23 (10). 2266-2272
27. Schmidt KT, Rosendahl M, Ernst E, et al. Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience. Fertil Steril. 2011 ; 95 (2). 695-701
28. von Wolff M, Donnez J, Hovatta O, et al. Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy-a technique in its infancy but already successful in fertility preservation. Eur J Cancer. 2009 ; 45 (9). 1547-1553